DARE vs. ENLV, CASI, JAN, THTX, DRRX, FBIO, VIRX, SPRB, IPA, and NXTC
Should you be buying Daré Bioscience stock or one of its competitors? The main competitors of Daré Bioscience include Enlivex Therapeutics (ENLV), CASI Pharmaceuticals (CASI), JanOne (JAN), Theratechnologies (THTX), DURECT (DRRX), Fortress Biotech (FBIO), Viracta Therapeutics (VIRX), Spruce Biosciences (SPRB), ImmunoPrecise Antibodies (IPA), and NextCure (NXTC). These companies are all part of the "pharmaceutical preparations" industry.
Enlivex Therapeutics (NASDAQ:ENLV) and Daré Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.
In the previous week, Daré Bioscience had 4 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 4 mentions for Daré Bioscience and 0 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.10 beat Daré Bioscience's score of 0.00 indicating that Daré Bioscience is being referred to more favorably in the news media.
Enlivex Therapeutics has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, Daré Bioscience has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.
Enlivex Therapeutics has higher earnings, but lower revenue than Daré Bioscience. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Daré Bioscience, indicating that it is currently the more affordable of the two stocks.
Daré Bioscience's return on equity of -71.00% beat Enlivex Therapeutics' return on equity.
1.0% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 6.7% of Daré Bioscience shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Daré Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Daré Bioscience received 303 more outperform votes than Enlivex Therapeutics when rated by MarketBeat users. However, 77.78% of users gave Enlivex Therapeutics an outperform vote while only 73.18% of users gave Daré Bioscience an outperform vote.
Enlivex Therapeutics presently has a consensus price target of $7.00, suggesting a potential upside of 351.61%. Daré Bioscience has a consensus price target of $6.00, suggesting a potential upside of 1,786.79%. Given Enlivex Therapeutics' higher possible upside, analysts plainly believe Daré Bioscience is more favorable than Enlivex Therapeutics.
Summary
Daré Bioscience beats Enlivex Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Daré Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Daré Bioscience Competitors List
Related Companies and Tools
